Press Release

# Frazier Healthcare Partners Completes Majority Investment in ATUM

**SEATTLE, November 17, 2026 - (BUSINESS WIRE) -** Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced the completion of its majority investment in ATUM (the "Company"). The transaction was completed in partnership with co-investors, including Frazier Life Sciences, and ATUM's existing founders and management team.

Originally founded as DNA2.0 in 2003, ATUM pioneered the modern bioengineering landscape by pairing machine learning with gene design, protein optimization, and cell line development via its Leap-In Transposase® platform. Today, ATUM's integrated solutions routinely enhance expression titers and ensure reliable scale-up to manufacturing, positioning ATUM as a trusted technology partner to major players across the biopharma sector.

Frazier Executive in Residence Milton Boyer will join the Board as Executive Chair, while Jeremy Minshull will continue to lead ATUM as Chief Executive Officer.

"ATUM's growth has been driven by our deep customer collaborations in solving complex scientific challenges. With our new partnership, we will expand our capacity, grow our infrastructure, and innovate faster – while remaining true to our mission and scientific values. I have never been more excited about the future of ATUM," said Jeremy Minshull, CEO and Co-Founder of ATUM.

"Frazier has a long history of investing in pharmaceutical services, but rarely do we see the combination of scientific leadership and market opportunity that we do in ATUM," said Jeremy Janson, Principal at Frazier Healthcare Partners. "We are thrilled to partner with Jeremy, Claes, Sridhar and the entire ATUM team to support scientific and technological innovation within the drug development ecosystem."

"This is an exciting opportunity for both Frazier and ATUM. It brings together the full breadth of resources that make Frazier a distinctive partner, including its Center of Excellence, Executive in Residence program and deep life sciences expertise, with a company that has established the benchmark for scientific leadership," said Milton Boyer, Frazier Executive in Residence. "We are incredibly enthusiastic about the potential of this partnership and the impact we can create in expanding ATUM's industry-leading biologics development platform."

Baird served as ATUM's exclusive financial advisor, while Paul Hastings provided legal counsel to the Company. Frazier was advised by William Blair and Goodwin Procter.

**About ATUM**
ATUM accelerates the transition of next-generation biotherapeutics from concept to clinic. By integrating machine learning algorithms, advanced gene synthesis, and high-performance cell line development, ATUM overcomes difficult expression and manufacturing hurdles for biopharma innovators worldwide. Based in Newark, California, the company delivers end-to-end bioengineering solutions that de-risk and shorten drug development timelines. Learn more at www.atum.bio.

**About Frazier Healthcare Partners:**
Founded in 1991, Frazier Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over the past 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier is headquartered in Seattle, Washington, with an office in New York City, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier, visit www.frazierhealthcare.com.

**Frazier Healthcare Media Contacts:**
**Carol Eckert**, Sr. Vice President of Investor Relations
Phone: 206.621.7200
Email: carol.eckert@frazierhealthcare.com
&
**Peter Tornatore**, Principal of Investor Relations
Phone: 206.600.1251
Email: peter.tornatore@frazierhealthcare.com